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Background:  To  ensure  adequate  protection  from  seasonal  inﬂuenza  in  the  US,  the Advisory  Committee  on
Immunization  Practices  recommends  vaccination  of all persons  aged 6  months  or older,  with  rare  excep-
tions.  It also  advises  starting  vaccination  as  soon  as available  and continuing  throughout  the inﬂuenza
season.  This  study  examined  US  seasonal  vaccination  trends  during  ﬁve  consecutive  inﬂuenza  seasons  in
privately-insured  children  and  adults.
Methods: This  retrospective,  observational  cohort  study  examined  trends  in  inﬂuenza  vaccination  during
the  2007–2008  through  2011–2012  inﬂuenza  seasons  using  administrative  claims  data  from  a large
national  insurer.
Results: The  size  of  analysis  population  ranged  from  1144,098  to 1245,487  (children,  ≥6  months-17  years
of  age)  and  from  3931,622  to  4158,223  (adults,  18–64  years  of age).  Vaccination  frequency  increased
through  2010–2011,  was  most  frequent  in  young  children,  and decreased  with  age.  Vaccination  rates
were  highest  in the Northeast  and  lowest  in the  West  and  were  higher  in individuals  with  frequent
outpatient  ofﬁce  visits  than  in  those  with  no or rare visits,  with  larger  differences  seen  in  children.
Between  2007  and  2011,  the  use  of  preservative-free  inactivated  vaccine  increased,  the  use  of  multidose
vaccines  containing  preservatives  decreased,  and the  use  of  live  attenuated  inﬂuenza  vaccines  increased
among  children  2–17  years  of  age.  From  2007–2008  through  2009–2010,  the  timing  of  vaccination  each
year  began  earlier  than  the  previous  one;  it remained  stable  from  2009–2010  through  2011–2012.
Conclusion: Annual  inﬂuenza  vaccination  claims  for privately-insured  children  and adults  increased  and
shifted  earlier  from  2007  through  2009–2011.  During  the  2011–2012  inﬂuenza  season,  25.4% of  children
aged  6  months-17  years  and  12.3%  of  adults  aged  18–64  years  were  vaccinated.  Increasing  inﬂuenza
vaccination  should  remain  a priority,  and  alternative  venues  for seasonal  inﬂuenza  vaccination  should
be  considered  in order  to meet  the  Healthy  People  2020  goal  of  80%  to  90%  coverage  among  children.
© 2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
In the United States, the populations recommended for routine
nnual inﬂuenza vaccination have expanded substantially in recent
ears. Before 2004, the US Centers for Disease Control and Preven-
ion’s (CDC) Advisory Committee on Immunization Practices (ACIP)
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264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unlicense (http://creativecommons.org/licenses/by-nc-nd/3.0/).
recommended seasonal inﬂuenza vaccination for individuals 50
years or older and individuals with high-risk medical conditions
[1]. Subsequently, the ACIP expanded recommendations for rou-
tine annual inﬂuenza vaccination to include all children 6 to 23
months of age in 2004 [2], 24 to 59 months of age in 2006 [3], 5 to
18 years of age in 2008 [4], and all adults and children ≥6 months
of age in 2010 [5]. Two  doses of inﬂuenza vaccination are recom-
mended in children 6 months to 8 years of age whose vaccination
status is unknown or who  are receiving an inﬂuenza vaccination
for the ﬁrst time and in children who  did not receive a dose of an
inﬂuenza A (H1N1) 2009 monovalent vaccine [5]. Healthy People
2020 goals aim for 80% or 90% inﬂuenza overall vaccination cover-
age in the US population [6]. Evaluations of US inﬂuenza vaccination
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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overage have demonstrated a steady increase in inﬂuenza
accination rates after implementation of these expanded rec-
mmendations [7]; however, it remains substantially below the
ealthy People 2020 goal.
Historically,  the majority of inﬂuenza vaccinations have been
dministered between October and December [8–11]. In 2007, the
CIP recommended initiation of seasonal inﬂuenza vaccination as
oon as vaccines became available [12]. Additionally, the ACIP rec-
mmended inﬂuenza vaccination throughout the entire inﬂuenza
eason, including the spring months [13]. Through 2012, multi-
le inﬂuenza vaccine formulations were available: multidose vial
nd preﬁlled syringe formulations of standard-dose inactivated
nﬂuenza vaccine (IIV), a high-dose IIV, and an intranasal live atten-
ated inﬂuenza vaccine (LAIV). The objective of this analysis was
o summarize vaccination trends in the US, including timing of
dministration, vaccine formulation by age group, and other factors
ssociated with inﬂuenza vaccination uptake.
. Methods
We  assessed seasonal inﬂuenza vaccination between 2007
nd 2012 using a national sample of administrative claims for
eographically-diverse, commercially-insured individuals.
.1.  Study design
This  retrospective, observational cohort study examined vacci-
ation trends among privately-insured children (6 months to 17
ears of age) and adults (18 to 64 years of age) in the US using
dministrative claims data from a large national insurer (Health-
ore Integrated Research Environment [HIRESM]) [14,15]. HIRESM
s a repository of a broad spectrum of medical, pharmacy, and lab-
ratory information on more than 43 million health plan members
rom across the US [14,15].
.2.  Data
The service models of the 14 commercial health plans included
n HIRESM encompass health maintenance organizations, point of
ervice, preferred provider organizations, and indemnity plans, and
pan most of the major regional population centers of the US. The
laims data tend to overrepresent the US Census data for ages 30–64
nd underrepresent the US Census data for ages 65 and older [15].
e selected all claims with a service date between 1 July 2006 and
 May  2012 and aggregated them by seasons: 2007–2008 through
011–2012. We  deﬁned each season as starting on 1 July and end-
ng on 30 April of respective years. To avoid duplicate claims, we
ncluded only the claims that had been paid or adjudicated.
This  study did not require IRB approval because researchers
hroughout the study only had access to a dataset that did not
nclude any identiﬁable personal information, preserving patient
nonymity and conﬁdentiality as well as ensuring full compliance
ith the Health Insurance Portability and Accountability Act of
996.
.3. Patient sample
The  analysis included actively enrolled members: those who
ad ≥12 months of continuous health plan enrollment before the
eginning of each year’s vaccination season (1 July) and continuous
ealth plan enrollment throughout the vaccination season (through
0 April). These subjects, grouped by the seasons, comprised the
enominators in all analyses, except weekly vaccination analy-
is. The denominators for weekly vaccination analyses included all
atients who were enrolled in the plans as of 1 July and throughout
he season (until 30 April). Because this study was  conducted with2 (2014) 6563–6568
data  from administrative databases, no personal information was
reported.
2.4. Measures
Seasonal inﬂuenza vaccination with IIV or LAIV was identi-
ﬁed based on seasonal inﬂuenza vaccination through the current
procedural terminology (CPT) and generic product identiﬁer (GPI)
codes. CPT codes were 90654, 90655, 90656, 90661, and 90662 for
split virus, preservative-free IIV; 90657 and 90658 for split virus,
preservative-containing IIV; 90659 for whole virus IIV; and 90660
for LAIV. GPI codes were 1710002021, 1710002023, 1710002044
for split virus, preservative-free IIV; 1710002020, and 1710002040
split virus, preservative-containing IIV; 1710002010 for whole
virus IIV; and 1710002050 for LAIV. For children (≤8 years of age),
who received two doses of vaccine, we counted only the ﬁrst vac-
cination.
The following characteristics were obtained in association with
each vaccination: patient age (calculated on the day of vaccina-
tion), geographic location (Northeast, Midwest, South, and West)
according to US census regional classiﬁcations [16], number of out-
patient ofﬁce visits to a healthcare provider (0 to ≥6) in the 12
months prior to the start of the vaccination season (referred to as
“number of outpatient ofﬁce visits” in this manuscript), and the
type of vaccine administered. The vaccines were classiﬁed into
three categories: preservative-free pre-ﬁlled syringes (PFS) of IIV,
preservative-containing multidose vials (MDV) of IIV, and LAIV
(intranasal preservative-free vaccine).
For weekly vaccination analyses, we deﬁned weeks as starting
on Mondays and ending on Sundays (according to the Inter-
national Organization for Standardization code ISO-8601) and
used EpochConverter (www.epochconverter.com) to assign week
counts.  For weekly analyses, we calculated the number of children
and adults vaccinated in each week and the cumulative total per-
centage of all patients vaccinated by the end of each week.
2.5.  Analyses
We  investigated seasonal inﬂuenza vaccination trends sepa-
rately for children and adults. The trends were stratiﬁed by patient
age categories (6 to 23 months; 2 to 4 years; 5 to 8 years, and 9
to 17 years for children and 18 to 49 years and 50 to 64 years for
adults), regions, number of outpatient ofﬁce visits, and the type of
vaccine. We  calculated age at time of vaccination for patients who
were vaccinated. For patients who  were not vaccinated, the median
date of vaccination during that season, based on patients who were
vaccinated, was  used. For the numerator of vaccination events, we
plotted weekly vaccination counts and recorded weeks at which
half of all patients were vaccinated. Because the size of the ana-
lyzed population was extremely large, the widths of the conﬁdence
intervals for the vaccination rate percent estimates by inﬂuenza
season, class of age, region, and type of vaccine were always lower
than ±1%; therefore any difference greater than 2% is statistically
signiﬁcant.
3. Results
3.1. Analysis population
For  seasonal analyses, the eligible analysis population ranged
between 1144,098 and 1245,487 for children and 3931,622 and
4158,223 for adults. The total number of vaccinated patients ranged
from 198,324 to 312,373 for children and 342,315 to 516,650 for
adults.
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Season
2008–2009
Season
2009–2010
Season
 2010–2011
Season
 2011–2012
Season
Midwest 8.4% 9.6% 11.2% 12.3% 12.3%
Northeast 14.0% 15.6% 16.0% 18.1% 16.9%
South 8.7% 10.2% 11.6% 13.3% 13.7%
West 4.8% 5.3% 5.8% 7.7% 7.5%
2007–2008
Season
2008–2009
Season
2009–2010
Season
 2010–2011
Season
 2011–2012
Season
Midwest 14.7% 19.8% 23.7% 24.3% 23.9%
Northeast 20.0% 24.4% 28.2% 31.3% 29.5%
South 18.0% 22.8% 26.5% 27.1% 26.3%
West 13.6% 16.8% 21.1% 23.3% 23.6%
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Midwest Northeast South Westig. 1. Percentages of subjects vaccinated against seasonal inﬂuenza. (A) Children;
B) Adults.
.2. Vaccination rates
During  the ﬁve inﬂuenza seasons, seasonal inﬂuenza vaccina-
ion rates in commercially insured children 6 months to 17 years
f age increased from 16.5% in the 2007–2008 season to 25.4%
n the 2011–2012 season. The frequency of vaccination decreased
ith advancing age in children, but this trend was reversed in
dults. Children 6 to 23 months of age had the highest likelihood
f vaccination against inﬂuenza (47–55%; Fig. 1A). Adults 50 to 64
ears of age were more likely to be vaccinated than those 18 to 49
ears of age (15–19% versus 5–9%, respectively; Fig. 1B). In all age
roups, the vaccination rates steadily increased from 2007–2008
hrough 2009–2010 season and then reached a plateau, with a
light decrease in the 2011–2012 inﬂuenza season (Fig. 1A and B).
With  respect to geography, children in the Northeast had the
ighest vaccination rates (20%–30%), whereas children in the West
ad the lowest (14–24%; Fig. 2A). Similar regional differences were
bserved with adult vaccination rates, which ranged from 5% to
8% (Fig. 2B). The regional differences for all ages varied by 6 to 8
ercentage points.
As  the number of outpatient ofﬁce visits increased, the probabil-
ty of seasonal inﬂuenza vaccination increased as well (Fig. 3A and
). Only 3–6% of children with no outpatient ofﬁce visit in the year
efore the vaccination season were vaccinated against inﬂuenza; inFig. 2. Region-speciﬁc percentages of eligible subjects with claims for seasonal
inﬂuenza  vaccination. (A) Children (6 months to 17 years of age); (B) Adults (18
to 64 years of age).
comparison, 27–38% of their counterparts with ≥6 outpatient ofﬁce
visits were vaccinated in the following season. In the absence of an
outpatient ofﬁce visit, vaccination in adults ranged from 1% to 3%;
in contrast, 13% to 18% of adults with 6 or more outpatient ofﬁce
visits were vaccinated. This pattern continued during all inﬂuenza
seasons.
The use of inﬂuenza vaccine types (IIV [PFS or MDV] or LAIV)
demonstrated a number of distinct patterns. For children 6 to 23
months of age (Fig. 4A), the proportion of inﬂuenza vaccinations
utilizing preservative-free PFS of IIV increased from 53% to 69%,
while that of preservative-containing MDV  of IIV decreased from
47% to 30%. Use of LAIV is not approved for children 6 to 23 months
of age; hence, LAIV use in this age category ranged from 0.3% to
1.1% and primarily occurred in children approaching their second
birthday. Among children 2 to 17 years of age (Fig. 4B), the use
of preservative-containing MDV  of IIV decreased from 69% to 35%,
whereas use of preservative-free PFS of IIV increased from 19% to
25%, and use of LAIV increased from 12% to 40% of the total. This
trend was similar in all pediatric age sub-groups with the exception
of those 2 to 4 years of age: their use of preservative-free PFS of
IIV remained relatively stable, with small ﬂuctuations, during the
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Fig. 4. Distribution of vaccines administered to children and adults. (A) 6 to 23
months of age; (B) 2 to 17 years of age; (C) 18 to 64 years of age. IIV = inactivatedig. 3. Percentages of eligible subjects with claims for seasonal inﬂuenza vaccina-
ion  by the number of outpatient ofﬁce visits in the year before vaccination season.
A) Children (6 months to 17 years of age); (B) Adults (18 to 64 years of age).
tudy period, but the trend was similar in preservative-containing
DV  of IIV and in LAIV. In adults, the most widely-used vaccine
as preservative-containing MDV  of IIV (76.5–93.9% of all doses),
ut use declined steadily over time and was offset by an increase
n the percentage of preservative-free PFS of IIV (5.6–22%). LAIV
nd high-dose preservative free PFS of IIV represented <1.5% of all
accines administered to adults 18 to 64 years of age (Fig. 4C).
The  within-season timing of inﬂuenza vaccination changed over
ime. From 2007–2008 through 2009–2010, inﬂuenza vaccination
eaked earlier each year, indicating a trend for early vaccination
Fig. 5A). Among vaccinated children, half were immunized by week
5 and 46 in 2006 and 2007, respectively. In later years, this thresh-
ld was achieved by week 43 in 2008 and 2010, week 42 in 2011,
nd week 40 in 2009. A similar pattern was observed in adults,
here half were vaccinated by week 45 in 2006, and week 44 in
007 and 2008; however, in later years, this threshold was  achieved
y week 42 in 2010 and 2011 and week 41 in 2009 (Fig. 5B). Each
ear, a distinct decline in pediatric and adult vaccinations occurred
n late November and December, coincident with the Thanksgiving
nd Christmas holidays..  Discussion
Among children and adults, inﬂuenza vaccination rates based on
rivate insurance claims increased during 2007–2008 through theinﬂuenza  vaccine; LAIV = preservative-free intranasal live attenuated inﬂuenza vac-
cine; MDV  = preservative-containing multidose vials of IIV; PFS = preservative-free
preﬁlled  syringes of IIV.
2009–2010 inﬂuenza seasons. Vaccination rates reached a plateau
in 2010–2011 and then decreased slightly during the 2011–2012
inﬂuenza season. This relative decrease in vaccination during the
2011–2012 season versus the 2009–2010 season is consistent with
the national inﬂuenza vaccination coverage estimates by the U.S.
Centers for Disease Control and Prevention (CDC) [17] and may be
attributed to an increased awareness due to the inﬂuenza pandemic
in 2009–2010. The increase in vaccination rates parallels the ACIP’s
expansion of seasonal inﬂuenza vaccination recommendations in
2008 (children 5–18 years of age) [4] and 2010 (all individuals ≥6
months of age) [5]. Consistent with previous reports, vaccination
rates decreased with age in children [17,18] and increased with age
in adults [17].
The  vaccination rates in the current analysis (25.4% in children
6 months to 17 years of age and 12.3% in adults 18 to 64 years of
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ge during season 2011–2012) were lower than those reported by
he CDC for the general U.S. population [19,20]. For the 2011–2012
nﬂuenza season, the CDC estimated national inﬂuenza vaccina-
ion rates of 51.5% in children 6 months to 17 years of age and
8.8% in adults [17]. This is likely because the current analysis only
valuated inﬂuenza vaccination for which an insurance claim was
enerated and, thus, did not capture inﬂuenza vaccinations that
ere not submitted for reimbursement. Conversely, vaccination
ates estimated by the CDC rely on telephone surveys that may
verestimate healthy behaviors.
The timing of seasonal vaccination clearly shifted to earlier
accination during the 2007–2008 through 2009–2010 seasons
nd receded slightly during the 2010–2011 and 2011–2012 sea-
ons. The most active vaccination months in commercially insured
hildren and adults were October and November (weeks 39
o 47), whereas in the general U.S. population, most seasonal
nﬂuenza vaccinations during 2009–2010 through 2011–2012 sea-
ons occurred in September and October [17]. To sustain the trend
or earlier seasonal inﬂuenza vaccination, vaccine manufacturers
hould ensure a stable and ample supply of inﬂuenza vaccines dur-
ng the ﬁrst months of vaccination season.
Substantial changes in the type of inﬂuenza vaccine used for
easonal vaccination occurred during the study period. In children
 to 23 months of age, preservative-free PFS of IIV became the pre-
ominant choice for seasonal vaccination. Likewise, LAIV became
he most frequently used vaccine in children 2 to 17 years of age. In
dults, the predominant formulation remained the preservative-
ontaining MDV  of IIV, although preservative-free PFS of IIV use
ncreased. These differences in type of inﬂuenza vaccine used
hroughout the study period may  be related to the types of vac-
ines that are offered and available in the healthcare setting at the
ime and may  not be entirely driven by patient preferences.
The  frequency of outpatient ofﬁce visits had a substantial impact
n vaccination rates. Physicians may  have a limited opportunity Number
onths to 17 years of age); (B) Adults (18 to 64 years of age).
to  offer seasonal inﬂuenza vaccination to patients who  have very
few or no outpatient ofﬁce visits, and, as a result, individuals
may remain unvaccinated. As noted above, our study would not
have captured individuals who  are vaccinated through alternative
venues such as public health programs, employer programs, or
schools. Among alternative vaccination venues, pharmacies and the
workplace accounted for 18% and 17% of adult vaccinations, respec-
tively, in 2012–2013; conversely, only 3% of children received an
inﬂuenza vaccination in a pharmacy and a negligible percentage
were immunized in the workplace [21]. Although school-based
vaccination programs continue to gain a foothold, only 6% of chil-
dren and 2% of adults were reported to have been immunized in
schools in 2012–2013 [21]. Therefore, expanding the availability
of inﬂuenza vaccines to include other locations such as pharma-
cies and schools should be explored to improve vaccine rates. In
some areas, school located inﬂuenza vaccination (SLIV) programs
have demonstrated that seasonal inﬂuenza vaccination rates were
higher (more than 4.4 times in elementary, 2 times – in middle,
and 1.7 times – in high school students) than in non-SLIV locations
[22]. Multiple SLIV programs have been very effective .at achieving
high vaccination rates [22–27]. Also, SLIV programs demonstrated
protection not only to the vaccinated children, but also to their
parents [22] and other members in the community [28]. A key
aspect of vaccination outside of the traditional medical home is
that information should be transmitted back to the medical home
to ensure accuracy of medical records and avoid duplicate vaccina-
tion.
The results of this analysis should be viewed in the context of its
limitations. This study included medical claims made for privately-
insured individuals. Capitated members of health maintenance
organizations, individuals without insurance coverage, cash pay
at pharmacy, or children receiving Medicaid or CHIP, or vaccines
through the Vaccines for Children program, were not included. We
chose not investigate immunization trends among adults ≥65 years
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ecause, for this patient population, private insurance represents a
econdary source of reimbursement after Medicare.
. Conclusions
Annual inﬂuenza vaccination claims for privately-insured chil-
ren and adults increased steadily from 2007–2008 to 2010–2011
nd reached a plateau in 2011–2012. Children appeared to lose their
n-ofﬁce vaccination opportunities as they grew older and as the
requency of their outpatient ofﬁce well-check and illness-related
isits diminished (this fact was true for adults as well). Other vac-
ination venues such as pharmacies, clinics, or school programs
ay help increase vaccination coverage in the US in order to meet
nﬂuenza vaccination targets of Healthy People 2020.
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